FR941019-2-00075 FR941019-2-00049 Food and Drug Administration [Docket No. 94N&hyph;0368] The Upjohn Co., et al.; Withdrawal of Approval of Seven Abbreviated Antibiotic Applications AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of seven abbreviated antibiotic applications (AADA's). The holders of the AADA's notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn. EFFECTIVE DATE: November 18, 1994. FOR FURTHER INFORMATION CONTACT: Lola E. Batson, Center for Drug Evaluation and Research (HFD&hyph;360), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;1038. SUPPLEMENTARY INFORMATION: The holders of the AADA's listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing. 1AADA No. 1Drug 1Applicant 61&hyph;651 Penicillin V Potassium Tablets, U.S.P., 500 milligrams (mg) The Upjohn Co., 7000 Portage Rd., Kalamazoo, MI 499001&hyph;0199. 61&hyph;656 Penicillin V Potassium for Oral Solution, U.S.P., 125 mg/5 milliliters (mL) and 250 mg/5 mL Do. 61&hyph;838 Penicillin G Potassium (nonsterile bulk, technical grade) SmithKline Beecham Pharmaceuticals, Four Falls Corporate Center, Rt. 23 and Woodmont Ave., P.O. Box 1510, King of Prussia, PA 19406. 62&hyph;158 Bacitracin Ophthalmic Ointment, U.S.P., 500 units/gram (g) Pharmaderm, Division of Altana Inc., 60 Baylis Rd., Melville, NY 11747. 62&hyph;440 Gentamicin Sulfate Ophthalmic Solution, U.S.P., 0.3% Pharmafair, Inc., 110 Kennedy Dr., Hauppauge, NY 11788. 62&hyph;558 Erythromycin Ethylsuccinate Oral Suspension, U.S.P., 400 mg/5 mL Do. 62&hyph;799 Bacitracin Ointment, U.S.P., 500 units/g Combe Inc., 1101 Westchester Ave., White Plains, NY 10604&hyph;3597. Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the AADA's listed above, and all amendments and supplements thereto, is hereby withdrawn, effective on November 18, 1994. Dated: October 4, 1994. Janet Woodcock, Director, Center for Drug Evaluation and Research. [FR Doc. 94&hyph;25908 Filed 10&hyph;18&hyph;94; 8:45 am] BILLING CODE 4160&hyph;01&hyph;F
